Withdrawal of Registration Statement (rw)
22 2월 2023 - 8:46PM
Edgar (US Regulatory)
RUBIUS THERAPEUTICS, INC.
C/O VERDOLINO & LOWEY, P.C.
124 WASHINGTON STREET, SUITE 101
FOXBOROUGH, MA
(508) 543-1270
February 22, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F. Street N.E.
Washington, D.C. 20549
| Re: | Rubius Therapeutics, Inc. – Request for Withdrawal
of Registration Statement on Form S-3 (File No. 333-265482) |
Ladies and Gentlemen:
Pursuant to Rule 477 promulgated
under the Securities Act of 1933, as amended (the “Securities Act”), Rubius Therapeutics, Inc. (the “Company”)
hereby requests that the Securities and Exchange Commission (the “Commission”) consent to the withdrawal of the Company’s
registration statement on Form S-3 (File No. 333-265482), together with the exhibits and amendments thereto, which was filed on June 8,
2022 (the “Registration Statement”), as of the date hereof or at the earliest practicable date hereafter. The Registration
Statement was declared effective by the Commission on June 21, 2022, but no securities have been issued or sold under the Registration
Statement.
Accordingly, the Company respectfully
requests, in accordance with Rule 457(p) under the Securities Act, that all fees paid to the Commission in connection with the filing
of the Registration Statement be credited to the Company’s account to be offset against the filing fee for any future registration
statement or registration statements.
If you have questions regarding
this request, please contact the Company’s legal counsel, Jacqueline Mercier, Esq., of Goodwin Procter LLP, at (617) 570-1762.
|
Very truly yours, |
|
|
/s/ Dannielle Appelhans |
|
Chief Executive Officer |
| cc: | Jennifer Kamocsay (General Counsel at Rubius Therapeutics, Inc.) |
Yasin Akbari (Goodwin Procter LLP)
Rubius Therapeutics (NASDAQ:RUBY)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Rubius Therapeutics (NASDAQ:RUBY)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Rubius Therapeutics Inc (나스닥)의 실시간 뉴스: 최근 기사 0
More Rubius Therapeutics, Inc. News Articles